Celltrion, Inc.

In the news

South Korea's Celltrion exports coronavirus tests to US Aug 13, 2020
Coronavirus: Week of July 12 to July 18, Australian PM seeks to delay parliament Jul 18, 2020
Glove makers and net stocks see COVID-19 boom in bear market Jul 1, 2020
SK Biopharm highlights drugs pipeline ahead of planned $800m IPO Jun 15, 2020
Takeda sells 18 drugs to South Korea's Celltrion in $278m deal Jun 12, 2020

Company Background

Celltrion is a South Korean pharmaceutical venture that develops "biosimilars" -- generic equivalents of biopharmaceuticals -- using microorganisms and animal cells. Remsima, a biosimilar treatment for rheumatoid arthritis, has been approved for sale in South Korea, Japan, Europe, Australia and Latin America.

Founded in 2002, Celltrion started out as a contract manufacturer for Western drug companies. It moved into biosimilars in 2008. The company's plants in South Korea can produce 200,000 liters of protein drugs per year.

In addition to well-known treatments Remsima and breast cancer drug Herzuma, the company develops and markets one to two new products a year. Celltrion plans to focus on developed markets, including Japan, the U.S. and Europe, where demand for biosimilars is growing rapidly.

Because Celltrion is a research and development-oriented company, its operating profit margin has remained high. It is one of the top companies on the Kosdaq market for startups in terms of market capitalization.

Business Summary

Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses. Its products include remsima and biosimilars. The company was founded on February 27, 1991 and is headquartered in Incheon, South Korea.

Financial Highlights

Dec 2021	KRW	USD
Revenue	1,911.60B	1,669.28M
Gross Profit	1,064.37B	929.45M
Operating income	752,471.48M	657.08M
Income before tax	751,917.45M	656.60M
Net income	575,093.26M	502.19M
EBITDA	972,131.45M	848.90M
Diluted EPS	3,952.18	3.45
Dividends Per Share	707.01	0.61
Total Assets	5,697.32B	4,792.70M
Total liabilities	1,623.74B	1,365.92M
Total equity	3,940.44B	3,314.77M
Operating cash flow	901,686.05M	787.38M
	Currency in KRW	Currency in USD

Historical Data

KRW | USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021
Revenue	949,079.96M	982,074.95M	1,128.45B	1,849.11B	1,911.60B
Gross Profit	685,318.99M	544,684.88M	623,118.64M	1,016.64B	1,064.37B
Operating income	507,771.41M	322,728.11M	381,535.86M	718,579.05M	752,471.48M
Income before tax	491,503.19M	302,159.30M	382,510.47M	654,561.59M	751,917.45M
Net income	382,467.03M	245,755.01M	301,030.34M	517,759.53M	575,093.26M
EBITDA	605,721.68M	447,554.58M	535,255.48M	892,388.45M	972,131.45M
Diluted EPS	2,582.75	1,652.66	2,074.44	3,560.57	3,952.18
Dividends Per Share	0	0	0	0	707.01
Total Assets	3,410.79B	3,590.82B	3,859.64B	5,020.12B	5,697.32B
Total liabilities	975,863.55M	992,561.59M	983,733.41M	1,589.54B	1,623.74B
Total equity	2,308.89B	2,486.50B	2,760.10B	3,307.67B	3,940.44B
Operating cash flow	482,870.20M	354,768.82M	468,031.66M	342,017.88M	901,686.05M

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021
Revenue	839.51M	892.37M	967.65M	1,567.19M	1,669.28M
Gross Profit	606.20M	494.93M	534.32M	861.64M	929.45M
Operating income	449.15M	293.25M	327.16M	609.02M	657.08M
Income before tax	434.76M	274.56M	328.00M	554.76M	656.60M
Net income	338.31M	223.30M	258.13M	438.82M	502.19M
EBITDA	535.79M	406.67M	458.98M	756.33M	848.90M
Diluted EPS	2.28	1.50	1.77	3.01	3.45
Dividends Per Share	0	0	0	0	0.61
Total Assets	3,186.01M	3,218.15M	3,337.49M	4,621.30M	4,792.70M
Total liabilities	911.55M	889.55M	850.64M	1,463.26M	1,365.92M
Total equity	2,156.73M	2,228.44M	2,386.70M	3,044.90M	3,314.77M
Operating cash flow	427.12M	322.36M	401.33M	289.87M	787.38M

Valuation Measures

Dec 2021
PER	47.94
ROA	10.73%
ROE	15.86%
Operating margin	39.36%
Profit margin	30.08%

Key executives

Chief Executive Officer & Director: Wu-Sung Ki
Finance Director: Ho-Seop Lee
Head-Legal & Compliance Support: Sung-Han Lee
Vice President: Sang-Joon Lee
Vice President: Jung-Won Yoon

Shareholders

SEO JUNG-JIN (22.1%)
National Pension Service of Korea (7.3%)
Temasek Holdings Pte Ltd. (Investment Management) (4.9%)
The Vanguard Group, Inc. (1.9%)
Celltrion, Inc. (1.7%)
BlackRock Fund Advisors (1.5%)
Mirae Asset Global Investments Co., Ltd. (0.9%)
Norges Bank Investment Management (0.8%)
Samsung Asset Management Co., Ltd. (0.7%)
BlackRock Advisors (UK) Ltd. (0.5%)

Contact Details

Website:http://www.celltrion.com
Address: 23 Academy-ro, Yeonsu-gu, Inchon, 22014, South Korea
Phone: +82.32.850.5000

Related Companies

Celltrion Asia Pacific Pte Ltd.
Celltrion Group Hong Kong Ltd.
Celltrion Biopharma Ltd.
Celltrion USA, Inc.
Celltrion Global Safety Data Center, Inc.
Celltrion Europe Ltd.
Vcell Healthcare Ltd.
Takeda Pharmaceuticals (Asia Pacific) Pte Ltd.
Celltrion Inc. Employee Stock Ownership ASSN.
Celltrion Pharm Inc.

Competitors

Novartis AG
Biocon Limited
AbbVie, Inc.
Pfizer Inc.
Merck & Co., Inc.
Amgen Inc.
Eli Lilly and Company
Biogen Inc.
Teva Pharmaceutical Industries Limited
Gilead Sciences, Inc.
AstraZeneca PLC
Fresenius SE & Co. KGaA
Bio-Thera Solutions, Ltd. Class A
Sanofi
Regeneron Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. Class A
Glenmark Pharmaceuticals Limited
GSK plc
Sam Chun Dang Pharm. Co., Ltd.
Viatris, Inc.
Alnylam Pharmaceuticals, Inc
Formycon AG
Luye Pharma Group Ltd.
Kirin Holdings Company, Limited
Sorrento Therapeutics, Inc.
Merck KGaA
FUJIFILM Holdings Corp
SAMSUNG BIOLOGICS Co., Ltd.
Cidara Therapeutics, Inc.
Generation Bio Co.

Last Updated on 25 Jan, 2023